The Board of Director of Endo, a specialty pharma and generics company, reports that the company’s President and CEO, Blaise Coleman, departed the company, effective August 29, 2024, and that the company has named Scott Hirsch, currently a member of Endo’s Board, as the company’s Interim CEO. The company has initiated a search for a new CEO and Hirsch will continue to serve as Interim CEO during the transition period while the search is ongoing. 

Hirsch joined the Endo Board of Directors in April 2024. He has over 20 years of experience in healthcare, investment management, and financial services and was formerly the CEO of Solta Medical, a medical aesthetics company, where he led growth of the global business through an expansion cycle. Prior to Solta, Hirsch was the President of the Ortho Dermatologics and OraPharma business segments and the Chief Business Officer of Bausch Health/Bausch & Lomb. 

Source: Endo